PLAU, plasminogen activator, urokinase, 5328

N. diseases: 439; N. variants: 8
Disease: Carcinoma breast stage IV ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.030 Biomarker disease BEFREE The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. 30783124 2019
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.030 Biomarker disease BEFREE Mesupron, the first-in-class inhibitor of urokinase-type plasminogen activator (uPA) is known to regulate cell proliferation and migration, and is under investigation for the treatment of metastatic breast cancer. 29216583 2018
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.030 AlteredExpression disease BEFREE Unfortunately, how sustained uPA expression is achieved in invasive/metastatic breast cancer cells is unknown. 22986534 2013